Holen Sie sich die Stockscreener-App
318.65
1.97%
-6.42
Schlusskurs vom Vortag:
$325.07
Offen:
$321.37
24-Stunden-Volumen:
947.58K
Relative Volume:
0.63
Marktkapitalisierung:
$42.26B
Einnahmen:
$3.71B
Nettoeinkommen (Verlust:
$313.75M
KGV:
141.18
EPS:
2.2571
Netto-Cashflow:
$465.38M
1W Leistung:
-4.27%
1M Leistung:
-9.42%
6M Leistung:
-28.78%
1J Leistung:
+30.85%
1-Tages-Spanne:
$315.20
$324.06
1-Wochen-Bereich:
$315.20
$334.80
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors - Yahoo Finance Singapore
Rafferty Asset Management LLC Sells 15,045 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. - Yahoo Finance
ALNY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Alnylam (NASDAQ: ALNY) CEO converts 5,921 RSUs into common stock - Stock Titan
Alnylam (ALNY) CFO receives 1,908 shares as final RSU tranche vests - Stock Titan
Alnylam (ALNY) CCO receives 1,666 shares from RSU vesting - Stock Titan
Alnylam (NASDAQ: ALNY) R&D chief sells 4,627 shares under plan - Stock Titan
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: An 84.90% Revenue Surge and 37.27% Upside Potential - DirectorsTalk Interviews
Paroxysmal Nocturnal Hemoglobinuria Market: Expanding Revenue Landscape to 2034 – DelveInsight | Alexion Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, AKARI Therapeutics, AstraZeneca - Barchart.com
Alnylam Pharmaceuticals receives positive recommendation from Canada's drug agency for public reimbursement of Amvuttra - marketscreener.com
Intellia gets FDA nod to resume second gene therapy trial after safety pause - marketscreener.com
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, - GlobeNewswire
Pullback Watch: What analysts say about Alnylam Pharmaceuticals Inc stockMarket Trend Report & Verified Momentum Watchlists - baoquankhu1.vn
Mitsubishi UFJ Asset Management Co. Ltd. Buys 9,002 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock - Finviz
Alnylam Phase 1 ALN-4285 Data Highlights Expanding RNAi Platform Potential - simplywall.st
DNB Asset Management AS Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ALNY PE Ratio & Valuation, Is ALNY Overvalued - Intellectia AI
American Century Companies Inc. Has $748.50 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Does Alnylam Pharmaceuticals (ALNY) Price Reflect Its RNAi Pipeline Potential? - Yahoo Finance
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Alnylam’s New Phase 1 ALN-4285 Trial: What Early Safety Data Could Mean for ALNY Investors - TipRanks
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Westfield Capital Management Co. LP - MarketBeat
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Case Study in Affordable Growth - ChartMill
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Pullback - simplywall.st
Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge - MSN
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
TD Asset Management Inc Sells 128,660 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Why Alnylam Pharmaceuticals Stock Slipped Today - AOL.com
Reassessing Alnylam Pharmaceuticals (ALNY) After Recent Share Price Weakness - simplywall.st
Will Alnylam’s (ALNY) 2025 Profitability and $2.26 Billion Shelf Filing Redefine Its Risk Profile? - simplywall.st
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference - BioSpace
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring Growth Potential with a 35.94% Upside - DirectorsTalk Interviews
Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily
Fiera Capital Corp Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Buys 7,091 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ANTIPODES PARTNERS Ltd Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. stock benefit from automationTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru
China Universal Asset Management Co. Ltd. Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge - Insider Monkey
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth - simplywall.st
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Shifting Trends in Biotechnology Mergers and Acquisitions - Intellectia AI
Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Freedom Capital - MarketBeat
Oligonucleotide Therapy Market to hit US$ 40.16 Billion by 2033 | - openPR.com
RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North - openPR.com
11,700 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Alberta Investment Management Corp - MarketBeat
1 Reason I'd Buy Eli Lilly Stock and Never Sell - AOL.com
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):